Cartalax
Bioregulatory Tripeptide · Cartilage & Connective Tissue Support
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Overview
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Supports cartilage maintenance and joint function.
Supports bone and connective tissue healing.
Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
Enhances collagen synthesis in connective tissue.
Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tripeptide
- Chain length
- 3 residues
- Molecular weight
- 350 Da
- Typical dose
- 100-200mcg oral (1-2 capsules) or 700-1400mcg injectable
- Frequency
- 1-2 times daily with meals (oral) or once daily (injectable)
- Cycle length
- 1-3 months depending on application
- Storage
- Oral capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Tripeptide
- Molecular weight
- 350 Da
- Chain length
- 3 residues
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Joint Support | Oral | 100-200mcg (1-2 capsules) | 1-2x daily with meals |
| Tissue Regeneration | SubQ | 700-1400mcg (10-20mcg/kg) | Daily |
| Skin Rejuvenation | Topical | 0.5-1ml solution | 2x daily |
Interactions
Complementary bioregulatory effects across organ systems.
May enhance synthesis while supplements provide raw materials.
Different mechanisms; no direct interaction.
Distinct action pathways; may complement effects.
Both affect tissue growth; monitor for excessive proliferation.
Complementary joint support mechanisms.
Quality checklist
- ✓Professional Russian packaging with holographic seals
- ✓Exactly 0.1mg (100mcg) AC-4 peptide complex per capsule
- ✓Clear Russian/English instructions specifying 'with meals'
- !Proper documentation required for authenticity
- !Import verification needed
- ×Missing holographic seals or professional packaging
- ×Unclear dosing instructions
What to expect
Safety
- No reported side effects in Russian clinical use when taken properly
- Well-tolerated in elderly patients
- Allergic reactions
- Digestive upset (rare with proper administration)
- No improvement after 3 months
- Unexpected symptoms
- Pregnancy and breastfeeding
- Active cancer (theoretical proliferation risk)
FAQ
How does Cartalax help cartilage if cartilage doesn't have blood vessels to deliver it?
Cartalax works through systemic effects on fibroblasts and gene expression. Once in circulation, it reaches fibroblasts throughout connective tissue, stimulating collagen production and suppressing matrix-degrading enzymes like MMP-9. This systemic fibroblast activation supports cartilage maintenance and collagen preservation even in avascular cartilage.
Can Cartalax reverse osteoarthritis or just prevent progression?
Russian clinical studies show efficacy in established osteoarthritis, osteochondrosis, and osteoporosis treatment. However, 'reverse' is overstated—Cartalax supports tissue repair and slows degeneration better than it rebuilds severely damaged cartilage. Results are best when cartilage damage is moderate, not advanced.
How long before joint pain improves on Cartalax?
Week 1-2 establishes baseline; minimal noticeable changes. Week 3-4 brings gradual improvement in joint comfort. Month 2 shows noticeable mobility improvements. Month 3 achieves maximum therapeutic effect. Results are cumulative with repeat cycles; 1-3 month cycles repeated annually produce best long-term joint health.
Is Cartalax safe for long-term use or does it carry cancer risk from cell proliferation?
Cartalax increases fibroblast proliferation while suppressing apoptosis. Theoretical concern exists regarding uncontrolled cell growth, but Russian clinical practice spanning decades shows no documented malignancy risk. Avoid use in active cancer; for healthy individuals, cyclic use (1-3 months on, breaks between) minimizes theoretical proliferation risk.